Organon

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Digital Health
    • Disease Management
  • Biotechnology

Other Names/Subsidiaries

  • Alydia Health
  • Dermavant Sciences
  • Forendo Pharma
  • Forendo Pharma Oy
  • Organon & Co.
  • Organon NV
See more in Biomedtracker

Latest on Organon

Scrip

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 
• By Sushmita Panda

Despite hailing OG-6219 as its “biggest potential opportunity” during its fourth-quarter earnings call in Feb 2025, Organon has decided to discontinue the drug’s development owing to its poor performa

Generics Bulletin

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

With US trade tariffs continuing to loom large over the pharma industry, Organon CEO Kevin Ali touched on the subject with respect to the firm’s biosimilars business during the company’s recent first-

Pink Sheet

Semaglutide For MASH Among Raft Of New EU Filings

 
• By Neena Brizmohun

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

Scrip

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,